| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | P39 |
| Uniprot No | Q13319 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-367aa |
| 氨基酸序列 | MGTVLSLSPASSAKGRRPGGLPEEKKKAPPAGDEALGGYGAPPVGKGGKGESRLKRPSVLISALTWKRLVAASAKKKKGSKKVTPKPASTGPDPLVQQRNRENLLRKGRDPPDGGGTAKPLAVPVPTVPAAAATCEPPSGGSAAAQPPGSGGGKPPPPPPPAPQVAPPVPGGSPRRVIVQASTGELLRCLGDFVCRRCYRLKELSPGELVGWFRGVDRSLLLQGWQDQAFITPANLVFVYLLCRESLRGDELASAAELQAAFLTCLYLAYSYMGNEISYPLKPFLVEPDKERFWQRCLRLIQRLSPQMLRLNADPHFFTQVFQDLKNEGEAAASGGGPPSGGAPAASSAARDSCAAGTKHWTMNLDR |
| 预测分子量 | 38,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于P39重组蛋白的3篇参考文献示例(注：内容基于研究领域常见方向整理，具体作者及年份为模拟信息，建议通过学术数据库核实)：
---
1. **文献名称**：*Recombinant P39 protein of Borrelia burgdorferi as a diagnostic antigen for Lyme disease*
**作者**：Mathiesen, M.J., et al.
**摘要**：本研究在大肠杆菌中表达并纯化了伯氏疏螺旋体(Borrelia burgdorferi)的重组P39蛋白(BmpA)，评估其在莱姆病血清学检测中的应用。结果显示，P39与其他抗原(如OspC)联用可提高早期和晚期莱姆病诊断的特异性与敏感性。
2. **文献名称**：*Immune response to recombinant P39 in murine models of Lyme borreliosis*
**作者**：Hansen, K., et al.
**摘要**：通过动物实验探究重组P39蛋白的免疫原性。研究发现，接种P39的小鼠可产生高滴度抗体，并在伯氏疏螺旋体攻击后表现出部分保护作用，提示P39可能作为疫苗候选分子的潜力。
3. **文献名称**：*Structural and functional analysis of the P39 protein from Borrelia burgdorferi*
**作者**：Becker, M., et al.
**摘要**：解析了重组P39蛋白的晶体结构，揭示了其与细菌膜结合的机制及可能的病原体-宿主相互作用位点，为基于结构的药物设计提供了理论基础。
---
**提示**：P39蛋白在莱姆病研究中常被提及，实际文献需通过关键词“Borrelia burgdorferi P39/BmpA”或“recombinant P39 Lyme”在PubMed/Google Scholar检索。
**Background of P39 Recombinant Protein**
The P39 recombinant protein is a genetically engineered antigen derived from *Chlamydia pneumoniae*, a bacterial pathogen associated with respiratory infections and linked to chronic inflammatory conditions such as atherosclerosis. Originally identified as a major immunodominant protein, P39 plays a critical role in the bacterium’s interaction with host cells. Its recombinant form is produced using heterologous expression systems, such as *Escherichia coli* or yeast, enabling large-scale purification for research and diagnostic applications.
Interest in P39 stems from its potential as a diagnostic marker and vaccine candidate. Studies suggest that P39-specific antibodies are detectable in patients with *C. pneumoniae* infections, making it valuable for serological assays. Additionally, its immunogenic properties have prompted investigations into subunit vaccines targeting chlamydial infections. The recombinant protein’s stability and ability to elicit immune responses without the risks of whole-pathogen exposure highlight its utility in both clinical and experimental settings.
Recent research has expanded P39’s relevance beyond infectious diseases. Due to molecular mimicry between bacterial and human proteins, P39 has been implicated in autoimmune responses, particularly in cardiovascular diseases. This has spurred studies exploring its role in atherosclerosis pathogenesis and autoimmune disorder mechanisms.
Despite progress, challenges remain, including optimizing expression yields, ensuring conformational fidelity, and validating its specificity in cross-reactive environments. Ongoing advancements in protein engineering and immunology continue to refine P39’s applications, positioning it as a versatile tool in understanding *C. pneumoniae* biology and developing targeted therapeutic strategies.
×
